Breast Cancer Risk in Menopausal Hormone Therapy: Progestin is the Primary Driver
The addition of progestin to estrogen is what increases breast cancer risk in menopausal hormone therapy—estrogen alone does not increase and may actually decrease breast cancer risk. This critical distinction fundamentally changes how we counsel patients about hormone therapy safety.
The Evidence is Clear and Consistent
The highest quality evidence comes from the Women's Health Initiative trials and FDA labeling, which demonstrate opposing effects:
Estrogen + Progestin: Increased Risk
Combined estrogen-progestin therapy (specifically conjugated equine estrogen 0.625 mg plus medroxyprogesterone acetate 2.5 mg) increases invasive breast cancer risk with a relative risk of 1.24, translating to 8 additional cases per 10,000 women-years 1, 2. The FDA label confirms that estrogen plus progestin increases breast cancer risk, with cancers being larger, more likely node-positive, and diagnosed at more advanced stages 3.
Estrogen Alone: Decreased Risk
In stark contrast, estrogen-only therapy (conjugated equine estrogen 0.625 mg daily) after hysterectomy was not associated with increased breast cancer risk (RR 0.80) and actually reduced breast cancer incidence by 8 cases per 10,000 women-years 1, 2. The FDA label explicitly states: "daily CE (0.625 mg)-alone was not associated with an increased risk of invasive breast cancer" 3.
Clinical Algorithm for Risk Assessment
For women WITH a uterus:
- Combined estrogen-progestin is required to prevent endometrial cancer
- Accept small increased breast cancer risk (8 additional cases per 10,000 women-years)
- Consider micronized progesterone over synthetic progestins—emerging evidence suggests micronized progesterone may have a more favorable breast cancer profile than synthetic progestins like medroxyprogesterone acetate 4, 5
For women WITHOUT a uterus (post-hysterectomy):
- Use estrogen-only therapy
- This actually provides breast cancer protection
- No progestin needed or recommended
Why This Matters: The Progestin Component
Recent meta-analyses confirm that synthetic progestins drive the breast cancer risk (OR 1.28), while micronized progesterone shows no significant association (OR 0.99) 4. The 2022 UK population-based study of over 43,000 breast cancer cases found that estrogens alone (bioidentical or animal-derived) were not associated with breast cancer, but formulations containing synthetic progestins increased risk by 28% 4.
Critical Pitfalls to Avoid
Don't add progestin unnecessarily: Women post-hysterectomy should never receive progestin—it adds breast cancer risk without benefit 3
Don't assume all hormone therapy is equal: The type of progestogen matters significantly. Observational studies suggest risk is "greater, and became apparent earlier, with estrogen plus progestin therapy as compared to the risk with estrogen-alone therapy" 3
Don't ignore duration: Risk increases with prolonged use and persists after discontinuation. The FDA notes risks "could last up to >10 years after discontinuation" 3
The Bottom Line for Counseling
When discussing breast cancer risk with patients considering menopausal hormone therapy:
- Post-hysterectomy patients: Estrogen-only therapy is preferred and may reduce breast cancer risk
- Patients with intact uterus: If progestin is required for endometrial protection, choose micronized progesterone over synthetic progestins when possible
- All patients: Use the lowest effective dose for the shortest duration needed for symptom control
The USPSTF guidelines conclude with high certainty that for chronic disease prevention, the harms of combined estrogen-progestin outweigh benefits, while noting the distinct profile of estrogen-alone therapy 1. This recommendation specifically addresses primary prevention—not symptom management, where the risk-benefit calculation differs substantially.